Disease · MONDO_0004577

corneal ulcer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. corneal ulcer. Diseases, record MONDO_0004577. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004577

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: corneal ulcer; Open Targets
Open Targets ID: MONDO_0004577; Open Targets
Other names: Ulcer, corneal, cornea ulcer disease, ulcer disease of cornea; Open Targets
Disease Ontology: DOID:8463; Disease Ontology
MeSH: D003320; MeSH
NCI Thesaurus: C50515; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 14 drugs, from PMDA; Open Targets

Drugs14

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LEVOFLOXACIN	CHEMBL5315124	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
MOXIFLOXACIN HYDROCHLORIDE	CHEMBL1200735	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
RIBOFLAVIN	CHEMBL1534	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CHLORHEXIDINE GLUCONATE	CHEMBL4297088	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MOXIFLOXACIN	CHEMBL32	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NATAMYCIN	CHEMBL1200656	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ROSE BENGAL FREE ACID	CHEMBL1208422	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ILOMASTAT	CHEMBL19611	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
BESIFLOXACIN	CHEMBL1201760	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOXYMETHYLCELLULOSE	CHEMBL1909054		Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 14

See all 14 drugs

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NTRK1	Neurotrophic tyrosine kinase receptor	1	Neurotrophic tyrosine kinase receptor agonist	Unknown	https://conductscience.org/library/genes/4914	Drugs and targets
NTRK2	Neurotrophic tyrosine kinase receptor	1	Neurotrophic tyrosine kinase receptor agonist	Unknown	https://conductscience.org/library/genes/4915	Drugs and targets
NTRK3	Neurotrophic tyrosine kinase receptor	1	Neurotrophic tyrosine kinase receptor agonist	Unknown	https://conductscience.org/library/genes/4916	Drugs and targets
OPRD1	Opioid receptors; mu/kappa/delta	1	Opioid receptors; mu/kappa/delta antagonist	Unknown	https://conductscience.org/library/genes/4985	Drugs and targets
OPRK1	Opioid receptors; mu/kappa/delta	1	Opioid receptors; mu/kappa/delta antagonist	Unknown	https://conductscience.org/library/genes/4986	Drugs and targets
OPRM1	Opioid receptors; mu/kappa/delta	1	Opioid receptors; mu/kappa/delta antagonist	Unknown	https://conductscience.org/library/genes/4988	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05110001	Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction	Phase 3	330	2026-01-30	Acanthamoeba Keratitis, Fungal Keratitis	CHLORHEXIDINE GLUCONATE, MOXIFLOXACIN, NATAMYCIN, ROSE BENGAL FREE ACID	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT05255107	Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers	Phase 2/3	468		Keratitis, Corneal Ulcer	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT05924893	The Use of Naltrexone Hydrochloride to Promote Healing in Patients With Resistant Non-infectious Corneal Ulcer	Not applicable	50		Cornea Ulcer	NALTREXONE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02717871	Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis	Phase 3	35		Keratitis; Infectious Disease (Manifestation)	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT02497365	Besifloxacin in Bacterial Keratitis	Not applicable	32		Bacterial Keratitis	BESIFLOXACIN, CEFAZOLIN, TOBRAMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT04573647	OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate		10		Neurotrophic Ulcer, Neurotrophic Keratitis, Neurotrophic Corneal Ulcer, Neurotrophic Keratoconjunctivitis	CENEGERMIN	Its record names the disease	ClinicalTrials.gov
NCT02068430	Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection	Phase 1	6		Corneal Ulcers	RIBOFLAVIN	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Standard Therapy vs Cross-Linking With Rose Bengal (RB-PDT): deaths from any cause	1 of 165	0 of 165	330	NCT05110001	Trial comparisons
Standard Therapy vs Cross-Linking With Rose Bengal (RB-PDT): serious adverse events	31 of 165	36 of 165	330	NCT05110001	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42348235	DERIVED	1	PubMed
41561665	DERIVED	1	PubMed
39192339	DERIVED	1	PubMed
39011096	DERIVED	1	PubMed
34996516	DERIVED	1	PubMed
32557558	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004577

GET https://conductscience.org/api/diseases/v1/MONDO_0004577/drugs

API reference For AI assistants